SPRIM Global Investments
- Company typePrivate
- Founded2008
- HeadquartersSingapore, Singapore
- Headcount11–50
- GTM typeB2B
- OfferingServices
SPRIM Global Investments firmographics
Firmographics- Name
- SPRIM Global Investments
- Legal name
- SPRIM Global Investments
- Website
- https://sprim.net
- Company type
- Private
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
SPRIM Global Investments industry classification
Industry- Product category
- Venture Capital - Life Sciences
- NAICS
- Portfolio Management and Investment Advice (523940), Investment Banking and Securities Intermediation (52315)
- SIC
- Services-Management Consulting Services (8742), Investment Advice (6282)
- akta.pro primary industry
- Capital Raising Advisory (Debt/Equity/Private Capital) (BPAHADAG)
Keywords
Where SPRIM Global Investments is headquartered
LocationHeadquarters
- HQ city
- Singapore
- HQ country
- Singapore
- HQ region
- Asia
Offices2 records
Markets served
SPRIM Global Investments business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Revenue model
- Venture Capital Returns: SPRIM Global Investments generates returns through equity investments in clinical-stage life sciences companies, from Series A through growth-stage, with active board participation. Returns realized through portfolio company exits via M&A, IPO, or other liquidity events.
- Credit/Debt Financing: Non-dilutive financing for clinical-stage companies structured around trial milestones to extend runway at critical inflection points. Includes interest-bearing debt facilities and convertible notes.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels3 records
SPRIM Global Investments product offering
Product offeringCore offering
SPRIM Global Investments is a privately held life sciences venture capital firm that deploys capital into clinical-stage therapeutics, medical devices, and pharma R&D services companies through direct equity investments (Series A through growth-stage) and non-dilutive credit facilities structured around clinical trial milestones. The firm operates as an operator-led investor, embedding alongside portfolio companies to provide strategic guidance across regulatory pathways, trial design, commercial launch, and global market access.
Differentiator
Problem solved
Functional benefit
Products and services
- Direct Equity Investment Equity capital deployed in clinical-stage life sciences companies from Series A through growth-stage, backed by deep diligence and active board participation. Targets biotechnology, medical device/MedTech, and pharma R&D services companies aligned with SGI's investment thesis.
- Credit (Non-Dilutive Financing) Non-dilutive financing for clinical-stage life sciences companies, structured around clinical trial milestones to extend runway at critical inflection points. Includes interest-bearing secured debt facilities, subordinated convertible notes, and milestone-based commitments.
Quantifiable outcome
- Vaxxas has raised more than $300 million to support programs, with almost $160 million injected into the Australian economy.
Companies that use SPRIM Global Investments
Customer profileSegments3 records
Ideal customer profiles1 record
SPRIM Global Investments technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration5 records
Feature3 records
SPRIM Global Investments partnerships and signals
Strategic signalPartnerships
15 partnerships are on record, tiered core, major and minor.
- Oracle Life SciencescoreObvioGo platform is directly integrated with Oracle Life Sciences Clinical One Data Collection for decentralized and hybrid clinical trials. This is an enterprise-grade integration enabling sponsors and CROs to deploy participant-facing trial technologies.
- Charité BerlinmajorTREOS Bio executed clinical collaboration agreement with Charité Berlin for OBERTO-202 Phase II clinical trial in MSS colorectal cancer.
- Junshi BiosciencesmajorTREOS Bio executed clinical collaboration agreement with Junshi Biosciences for OBERTO-202 trial evaluating PolyPEPI1018 with toripalimab (PD-1 inhibitor) in MSS colorectal cancer.
- RochemajorTREOS Bio has partnerships with Roche for clinical development of PolyPEPI1018 in combination with atezolizumab.
- Mayo ClinicmajorTREOS Bio has partnerships with Mayo Clinic for Phase I/II clinical trials in MSS colorectal cancer.
- SK biosciencemajorVaxxas has vaccine programs underway in partnership with SK bioscience for HD-MAP vaccine delivery technology.
- Coalition for Epidemic Preparedness Innovations (CEPI)majorVaxxas has vaccine programs underway in partnership with CEPI for HD-MAP vaccine delivery technology.
- Wellcome TrustmajorVaxxas has vaccine programs underway in partnership with Wellcome for HD-MAP vaccine delivery technology.
- US GovernmentmajorVaxxas has vaccine programs underway in partnership with the US Government for HD-MAP vaccine delivery technology.
- Bill & Melinda Gates FoundationmajorVaxxas has vaccine programs underway in partnership with the Gates Foundation for HD-MAP vaccine delivery technology.
- Guardant HealthmajorGuardant Health made a strategic investment in ObvioHealth to accelerate deployment of oncology clinical trials globally, strengthening domain expertise in oncology and enabling streamlined trial deployment.
- DedalusminorObvioHealth announced a groundbreaking partnership with Dedalus Group to unite real-world clinical trial data.
- NovotechminorObvioHealth partnered with Novotech for virtual clinical trials capabilities expansion.
- Firefly NeuroscienceminorSTALICLA partnered with Firefly Neuroscience to develop EEG biomarkers for patient subgroups with ASD using the DEPI and BNA platforms.
- NovartiscoreSTALICLA signed exclusive in-licensing agreement with Novartis to develop mavoglurant for substance-use disorder and neurodevelopmental disorders.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
SPRIM Global Investments competitors and assessment
Company assessmentDirect peers
- Sofinnova Partners: European life sciences VC investing across clinical-stage therapeutics and medical devices from Series A through growth — directly comparable to SPRIM in mandate, stage focus, and active board participation.
- Forbion: European life sciences-focused VC investing in clinical-stage therapeutics and medtech, similar in stage focus and operational engagement model to SPRIM.
- OneVentures: Australian life sciences VC that co-invested alongside SPRIM in Vaxxas (A$90M Series D) and Prota Therapeutics; similar focus on clinical-stage Australian biotech with active board participation.
- Brandon Capital: Australian life sciences VC that co-invested alongside SPRIM in the Vaxxas Series D; comparable stage focus, geography, and active engagement model.
- LSP (Life Sciences Partners): European life sciences VC focused on clinical-stage therapeutics and medical devices — closely comparable to SPRIM in stage focus, European footprint, and active board model.
- Medicxi: European life sciences VC investing in clinical-stage therapeutics across multiple therapeutic areas; comparable to SPRIM in stage focus and founder-friendly operator engagement.
Broad incumbents
- OrbiMed: Large global healthcare-dedicated investment firm covering public and private life sciences; overlaps with SPRIM in clinical-stage biotech investing but with materially larger AUM and broader mandate.
- Baker Bros. Advisors: Healthcare/biotech-focused long-only investment manager that invests across public and private clinical-stage life sciences; broader incumbent with overlapping clinical-stage biotech exposure.
- ARCH Venture Partners: Large US-based biotech and technology VC that invests across clinical-stage life sciences; comparable stage overlap with SPRIM but at materially larger fund size and broader portfolio.
- RA Capital Management: Healthcare-focused crossover fund investing across public and private clinical-stage life sciences; overlapping deal universe with SPRIM but at larger scale and with crossover capabilities.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
SPRIM Global Investments social profiles
Digital presenceSPRIM Global Investments financial estimates
Financial estimateRevenue estimate
Valuation estimate
SPRIM Global Investments leadership team
Management profileNumber of profiles
Profiles3 records
SPRIM Global Investments funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SPRIM Global Investments M&A and investment
M&A and investmentM&A
Investments19 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SPRIM Global Investments
What does SPRIM Global Investments do?
SPRIM Global Investments is a privately held life sciences venture capital firm that deploys capital into clinical-stage therapeutics, medical devices, and pharma R&D services companies through direct equity investments (Series A through growth-stage) and non-dilutive credit facilities structured around clinical trial milestones. The firm operates as an operator-led investor, embedding alongside portfolio companies to provide strategic guidance across regulatory pathways, trial design, commercial launch, and global market access.
Is SPRIM Global Investments a public or private company?
SPRIM Global Investments is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was SPRIM Global Investments founded?
SPRIM Global Investments was founded in 2008. It employs 11 to 50 people.
Where is SPRIM Global Investments based?
SPRIM Global Investments is headquartered in Singapore, Singapore, in the Asia region.
How does SPRIM Global Investments make money?
Two revenue lines are on record. Venture Capital Returns are the primary driver. The others are credit/Debt Financing.
Who are SPRIM Global Investments's main competitors?
Direct peers on record are Sofinnova Partners, Forbion, OneVentures, Brandon Capital, LSP (Life Sciences Partners) and Medicxi. Broad incumbents are OrbiMed, Baker Bros. Advisors, ARCH Venture Partners and RA Capital Management.
Does SPRIM Global Investments have an API?
No public API is recorded for SPRIM Global Investments.
What industry is SPRIM Global Investments in?
SPRIM Global Investments's product category is Venture Capital - Life Sciences. Its primary akta.pro industry code is BPAHADAG, Capital Raising Advisory (Debt/Equity/Private Capital). Its NAICS code is 523940 and its SIC code is 8742.